Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
Tel: |
021-65675885 18964387627 |
Email: |
customer_service@efebio.com |
Products Intro: |
Product Name:Glucosylceramide synthase-IN-1 CAS:2601393-20-6 Purity:95% Package:2mg
|
Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
Tel: |
021-59167510 18117107507 |
Email: |
vip@med-life.cn |
Products Intro: |
Product Name:Glucosylceramide synthase-IN-1 CAS:2601393-20-6 Purity:>=99% Package:100mg;10mg;5mg;50mg
|
Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:Glucosylceramide synthase-IN-1 CAS:2601393-20-6 Purity:0 Package:2mg/RMB 2650
|
|
| 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]- Basic information |
Product Name: | 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]- | Synonyms: | 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]-;Glucosylceramide synthase-IN-1 | CAS: | 2601393-20-6 | MF: | C24H20F4N2O3 | MW: | 460.42 | EINECS: | | Product Categories: | | Mol File: | 2601393-20-6.mol | |
| 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]- Chemical Properties |
Boiling point | 575.6±50.0 °C(Predicted) | density | 1.363±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | form | Solid | pka | 14.39±0.29(Predicted) | color | White to off-white |
| 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]- Usage And Synthesis |
Biological Activity | Glucosylceramide synthase-IN-1 (T-036) a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research[1].
Glucosylceramide synthase-IN-1 (T-036) potently reduces the GCS product, catalyze glucosylceramide (GlcCer), in the fibroblasts with Gaucher's disease (EC50 of 7.6 nM)[1].
Glucosylceramide synthase-IN-1 (T-036) has good oral exposure (BA = 67%) and moderate brain penetration (Kpuu,brain = 0.11). Administration of a single dose of Glucosylceramide synthase-IN-1 (T-036) reduces GlcCer in the plasma and cerebral cortex of wild-type mice, and administration of Glucosylceramide synthase-IN-1 (T-036) for 2 months significantly reduces glucosylsphingosine (GlcSph) in the cerebral cortex of the Gaucher's disease mouse model[1]. | References | [1]. Yuta Tanaka, et al. Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore. J Med Chem. 2022 Mar 10;65(5):4270-4290 |
| 1H-Pyrrolo[3,4-c]pyridin-1-one, 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]- Preparation Products And Raw materials |
|